Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 5/20 | 0.74 |
| ▸ | CHUK | O15111 | 4/20 | 0.74 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.74 |
| ▸ | IGF1R | P08069 | 2/20 | 0.74 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.74 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.74 |
| ▸ | JAK2 | O60674 | 1/20 | 0.74 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.74 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.74 |
| ▸ | PAK4 | O96013 | 1/20 | 0.74 |
| ▸ | CSF1R | P07333 | 1/20 | 0.74 |
| ▸ | RET | P07949 | 1/20 | 0.74 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.74 |
| ▸ | PRKACA | P17612 | 1/20 | 0.74 |
| ▸ | FLT1 | P17948 | 1/20 | 0.74 |
| ▸ | LTK | P29376 | 1/20 | 0.74 |
| ▸ | GRK5 | P34947 | 1/20 | 0.74 |
| ▸ | KDR | P35968 | 1/20 | 0.74 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.74 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL730230 | 0.87 | CCNK (0.63) | IKBKBCHUKAURKBIGF1RDYRK1B | |
| SCHEMBL857275 | 0.85 | IKBKB (1.00) | IKBKBCHUKAURKBIGF1RDYRK1B | |
| SCHEMBL2240671 | 0.84 | AURKB (0.71) | IKBKBCHUKAURKBIGF1RDYRK1B | |
| SCHEMBL4790931 | 0.83 | IKBKB (0.57) | IKBKBCHUKAURKBIGF1RDYRK1B | |
| SCHEMBL12127926 | 0.82 | IKBKB (0.70) | IKBKBCHUKAURKBIGF1RDYRK1B | |
| SCHEMBL4771643 | 0.82 | IKBKB (0.70) | IKBKBCHUKAURKBIGF1RDYRK1B | |
| SCHEMBL12127858 | 0.82 | IKBKB (0.93) | IKBKBCHUKAURKBIGF1RDYRK1B | |
| SCHEMBL31065020 | 0.82 | IKBKB (0.70) | IKBKBCHUKAURKBIGF1RDYRK1B | |
| SCHEMBL4792517 | 0.82 | IKBKB (0.70) | IKBKBCHUKAURKBIGF1RDYRK1B | |
| SCHEMBL1718742 | 0.82 | NUDT1 (0.73) | IKBKBCHUKAURKBIGF1RDYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208053-A1 | Fused heterobicyclic kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | claimed |
| US-20110282056-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-11-17 | — | — | US | disclosed |
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| CN-102143746-A | CDK modulators | EXELIXIS INC | 2011-08-03 | — | — | CN | disclosed |
| US-7943616-B2 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-17 | — | — | US | disclosed |
| WO-2009094123-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2009-07-30 | — | — | WO | disclosed |
| EP-1979353-A2 | FUSED HETEROBICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20070208053-A1 | Fused heterobicyclic kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070208053-A1 | Fused heterobicyclic kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070208053-A1 | Fused heterobicyclic kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
| WO-2007084667-A2 | FUSED HETEROBICYCLIC KINASE INHIBITORS | OSI PHARMACEUTICAL, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084667-A2 | FUSED HETEROBICYCLIC KINASE INHIBITORS | OSI PHARMACEUTICAL, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| US-7227020-B2 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2007-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110282056-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MAP3K19, MAP3K20, MAP3K1 | IKBKB 436/4885CHUK 212/4885AURKB 296/4885 |
| US-20110201599-A1 | CDK Modulators | CDK3, CDK1, CDKL1 | IKBKB 246/4885CHUK 163/4885AURKB 58/4885 |
| US-20070208053-A1 | Fused heterobicyclic kinase inhibitors | MAP2K5, MAP2K7, MAP2K2 | IKBKB 138/4885CHUK 31/4885AURKB 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.